date,title,source
Nov-14-18,Pulmatrix Reports Q3 2018 Results,PR Newswire
Nov-15-18,"Pulmatrix to Present Results from the Pulmazole (PUR1900) Phase 1/1b Study at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology",PR Newswire
Nov-21-18,Pulmatrix Announces Positive Final Results from the Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE Formulation of Itraconazole,PR Newswire
Nov-29-18,Pulmatrix Announces $3.0 Million Registered Direct Offering,PR Newswire
Jan-28-19,"Pulmatrix, Inc. Announces Proposed Public Offering of Common Stock",PR Newswire
Jan-30-19,"Pulmatrix, Inc. Announces Pricing of Public Offering of Common Stock",PR Newswire
Jan-30-19,"Pulmatrix, Inc. Announces Proposed Public Offering of Common Stock",PR Newswire
Jan-31-19,"Pulmatrix, Inc. Announces Closing of Public Offering of Common Stock",PR Newswire
Feb-05-19,"Pulmatrix, Inc. Announces 1-for-10 Reverse Stock Split",PR Newswire
Feb-05-19,"Pulmatrix, Inc. Announces Closing of Public Offering of Common Stock",PR Newswire
Feb-06-19,4 Biotech Stocks Making Moves on Wednesday (2/6/19),ACCESSWIRE
Feb-06-19,"Pulmatrix, Inc. Announces Termination of Planned Offering Pursuant to Registration Statement on Form S-1",PR Newswire
Feb-07-19,Pulmatrix Receives IND Approval for Pulmazole Phase 2 Clinical Study,PR Newswire
Feb-08-19,"Pulmatrix, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market",PR Newswire
